# Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors

> **NCT04830501** · PHASE1 · COMPLETED · sponsor: **TransThera Sciences (Nanjing), Inc.** · enrollment: 11 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** TT-00434

## Key facts

- **NCT ID:** NCT04830501
- **Lead sponsor:** TransThera Sciences (Nanjing), Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-12
- **Primary completion:** 2023-10-18
- **Final completion:** 2023-10-18
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830501, "Study of the of the Safety and Tolerability of TT-00434 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04830501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*